COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Press release providing information on the total number of voting rights and shares as of 30 April 2026, in compliance with French commercial code and regulations -
COMMUNIQUÉ DE PRESSE
Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors
Immunic appoints Michael W. Bonney as Board Chair, bringing over 30 years of biopharmaceutical experience. Bonney led successful commercialization of Avonex® for MS. Exciting plans for future therapies -
COMMUNIQUÉ DE PRESSE
White Gold Corp. Identifies High-Priority Copper, Gold & Multi Element Porphyry and Epithermal Targets at Guilder and Mt. Hart Targets Following IP Geophysics Program
White Gold Corp. announces successful results of IP geophysical programs on Guilder and Mt. Hart targets in White Gold District, Yukon, Canada. Programs identify drill-ready chargeability anomalies -
COMMUNIQUÉ DE PRESSE
Macro Advisory Partners Appoints Wolfgang Schmidt as Senior Advisor
Macro Advisory Partners appoints Wolfgang Schmidt as Senior Advisor, bringing deep expertise in European affairs, foreign policy, and economic statecraft. Schmidt joins as geopolitical complexity rises in Europe -
-
-
COMMUNIQUÉ DE PRESSE
Ajout sur Onde de l'avis financier au 31-03-2026 en complément du communiqué de presse déjà diffusé le 24 avril
Communiqué de presse: Résultats financiers trimestriels du Crédit Agricole du Languedoc au 31 mars 2026: PNB en hausse de 5,3%. Encours de crédits et collecte en progression. Ratio de solvabilité solide -
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Provides an Update regarding Jury Verdict in AMITIZA® (lubiprostone) Antitrust Litigation in the U.S. and Related Revision to FY2025 Financial Results
Takeda reports adverse jury verdict in AMITIZA antitrust case in the U.S., impacting FY2025 financial results. Company to pursue post-trial motions and appeal
